Now showing items 383-402 of 1100

    • Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer. 

      Hunt, A; Hanson, I; Dunlop, A; Barnes, H; Bower, L; Chick, J; Cruickshank, C; Hall, E; Herbert, T; Lawes, R; McQuaid, D; McNair, H; Mitchell, A; Mohajer, J; Morgan, T; Oelfke, U; Smith, G; Nill, S; Huddart, R; Hafeez, S (2020-11)
      Whole bladder magnetic resonance image-guided radiotherapy using the 1.5 Telsa MR-linac is feasible. Full online adaptive planning workflow based on the anatomy seen at each fraction was performed. This was delivered within ...
    • Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer. 

      Mohajer, J; Dunlop, A; Mitchell, A; Goodwin, E; Nill, S; Oelfke, U; Tree, A (2021-01)
      The drive towards hypofractionated prostate radiotherapy is motivated by a low alpha/beta ratio for prostate cancer (1 to 3 Gy) compared to surrounding organs at risk, implying an improved therapeutic ratio with increasing ...
    • Feasibility of palliating recurrent gynecological tumors with MRGHIFU: comparison of symptom, quality-of-life, and imaging response in intra and extra-pelvic disease. 

      Imseeh, G; Giles, SL; Taylor, A; Brown, MRD; Rivens, I; Gordon-Williams, R; Ter Haar, G; deSouza, NM
      Objective To document longitudinal symptom, quality-of-life and imaging response in patients with recurrent gynecological tumors treated with magnetic resonance guided high intensity focused ultrasound (MRgHIFU), and compare ...
    • Feasibility of using ultrasound for real-time tracking during radiotherapy. 

      Hsu, A; Miller, NR; Evans, PM; Bamber, JC; Webb, S (2005-06)
      This study was designed to examine the feasibility of utilizing transabdominal ultrasound for real-time monitoring of target motion during a radiotherapy fraction. A clinical Acuson 128/XP ultrasound scanner was used to ...
    • Feasibility study of combined dynamic imaging and lymphaticovenous anastomosis surgery for breast cancer-related lymphoedema. 

      Khan, AA; Hernan, I; Adamthwaite, JA; Ramsey, KWD (2019-01)
      Background Breast cancer-related lymphoedema (BCRL) presents a significant healthcare burden and adversely affects quality of life of breast cancer survivors. A prospective feasibility study was performed on lymphaticovenous ...
    • Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour. 

      Jay, APM; Aldiwani, M; O'Callaghan, ME; Pearce, AK; Huddart, RA; Mayer, E; Reid, AH; Nicol, DL
      Background Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr.Objective To review features of ...
    • Fever of Unknown Origin: the Value of FDG-PET/CT. 

      Kouijzer, IJE; Mulders-Manders, CM; Bleeker-Rovers, CP; Oyen, WJG (2018-03)
      Fever of unknown origin (FUO) is commonly defined as fever higher than 38.3°C on several occasions during at least 3 weeks with uncertain diagnosis after a number of obligatory investigations. The differential diagnosis ...
    • FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. 

      Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; Manodoro, F; Fenwick, K; Bliss, J; Yarnold, J; Somaiah, N (2018-08)
      Background Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline ...
    • Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. 

      Andtbacka, RHI; Collichio, F; Harrington, KJ; Middleton, MR; Downey, G; Ӧhrling, K; Kaufman, HL (2019-06-06)
      Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients ...
    • Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. 

      Fachal, L; Aschard, H; Beesley, J; Barnes, DR; Allen, J; Kar, S; Pooley, KA; Dennis, J; Michailidou, K; Turman, C; Soucy, P; Lemaçon, A; Lush, M; Tyrer, JP; Ghoussaini, M; Moradi Marjaneh, M; Jiang, X; Agata, S; Aittomäki, K; Alonso, MR; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arason, A; Arndt, V; Aronson, KJ; Arun, BK; Auber, B; Auer, PL; Azzollini, J; Balmaña, J; Barkardottir, RB; Barrowdale, D; Beeghly-Fadiel, A; Benitez, J; Bermisheva, M; Białkowska, K; Blanco, AM; Blomqvist, C; Blot, W; Bogdanova, NV; Bojesen, SE; Bolla, MK; Bonanni, B; Borg, A; Bosse, K; Brauch, H; Brenner, H; Briceno, I; Brock, IW; Brooks-Wilson, A; Brüning, T; Burwinkel, B; Buys, SS; Cai, Q; Caldés, T; Caligo, MA; Camp, NJ; Campbell, I; Canzian, F; Carroll, JS; Carter, BD; Castelao, JE; Chiquette, J; Christiansen, H; Chung, WK; Claes, KBM; Clarke, CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée, JM; Cornelissen, S; Couch, FJ; Cox, A; Cross, SS; Cybulski, C; Czene, K; Daly, MB; de la Hoya, M; Devilee, P; Diez, O; Ding, YC; Dite, GS; Domchek, SM; Dörk, T; Dos-Santos-Silva, I; Droit, A; Dubois, S; Dumont, M; Duran, M; Durcan, L; Dwek, M; Eccles, DM; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Fletcher, O; Floris, G; Flyger, H; Foretova, L; Foulkes, WD; Friedman, E; Fritschi, L; Frost, D; Gabrielson, M; Gago-Dominguez, M; Gambino, G; Ganz, PA; Gapstur, SM; Garber, J; García-Sáenz, JA; Gaudet, MM; Georgoulias, V; Giles, GG; Glendon, G; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Tibiletti, MG; Greene, MH; Grip, M; Gronwald, J; Grundy, A; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hartikainen, JM; Hartman, M; He, W; Healey, CS; Heemskerk-Gerritsen, BAM; Heyworth, J; Hillemanns, P; Hogervorst, FBL; Hollestelle, A; Hooning, MJ; Hopper, JL; Howell, A; Huang, G; Hulick, PJ; Imyanitov, EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators; Isaacs, C; Iwasaki, M; Jager, A; Jakimovska, M; Jakubowska, A; James, PA; Janavicius, R; Jankowitz, RC; John, EM; Johnson, N; Jones, ME; Jukkola-Vuorinen, A; Jung, A; Kaaks, R; Kang, D; Kapoor, PM; Karlan, BY; Keeman, R; Kerin, MJ; Khusnutdinova, E; Kiiski, JI; Kirk, J; Kitahara, CM; Ko, Y-D; Konstantopoulou, I; Kosma, V-M; Koutros, S; Kubelka-Sabit, K; Kwong, A; Kyriacou, K; Laitman, Y; Lambrechts, D; Lee, E; Leslie, G; Lester, J; Lesueur, F; Lindblom, A; Lo, W-Y; Long, J; Lophatananon, A; Loud, JT; Lubiński, J; MacInnis, RJ; Maishman, T; Makalic, E; Mannermaa, A; Manoochehri, M; Manoukian, S; Margolin, S; Martinez, ME; Matsuo, K; Maurer, T; Mavroudis, D; Mayes, R; McGuffog, L; McLean, C; Mebirouk, N; Meindl, A; Miller, A; Miller, N; Montagna, M; Moreno, F; Muir, K; Mulligan, AM; Muñoz-Garzon, VM; Muranen, TA; Narod, SA; Nassir, R; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nikitina-Zake, L; Norman, A; Offit, K; Olah, E; Olopade, OI; Olsson, H; Orr, N; Osorio, A; Pankratz, VS; Papp, J; Park, SK; Park-Simon, T-W; Parsons, MT; Paul, J; Pedersen, IS; Peissel, B; Peshkin, B; Peterlongo, P; Peto, J; Plaseska-Karanfilska, D; Prajzendanc, K; Prentice, R; Presneau, N; Prokofyeva, D; Pujana, MA; Pylkäs, K; Radice, P; Ramus, SJ; Rantala, J; Rau-Murthy, R; Rennert, G; Risch, HA; Robson, M; Romero, A; Rossing, M; Saloustros, E; Sánchez-Herrero, E; Sandler, DP; Santamariña, M; Saunders, C; Sawyer, EJ; Scheuner, MT; Schmidt, DF; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schöttker, B; Schürmann, P; Scott, C; Scott, RJ; Senter, L; Seynaeve, CM; Shah, M; Sharma, P; Shen, C-Y; Shu, X-O; Singer, CF; Slavin, TP; Smichkoska, S; Southey, MC; Spinelli, JJ; Spurdle, AB; Stone, J; Stoppa-Lyonnet, D; Sutter, C; Swerdlow, AJ; Tamimi, RM; Tan, YY; Tapper, WJ; Taylor, JA; Teixeira, MR; Tengström, M; Teo, SH; Terry, MB; Teulé, A; Thomassen, M; Thull, DL; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Torres, D; Torres-Mejía, G; Troester, MA; Truong, T; Tung, N; Tzardi, M; Ulmer, H-U; Vachon, CM; van Asperen, CJ; van der Kolk, LE; van Rensburg, EJ; Vega, A; Viel, A; Vijai, J; Vogel, MJ; Wang, Q; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Wildiers, H; Winqvist, R; Wolk, A; Wu, AH; Yannoukakos, D; Zhang, Y; Zheng, W; Hunter, D; Pharoah, PDP; Chang-Claude, J; García-Closas, M; Schmidt, MK; Milne, RL; Kristensen, VN; French, JD; Edwards, SL; Antoniou, AC; Chenevix-Trench, G; Simard, J; Easton, DF; Kraft, P; Dunning, AM (2020-01-07)
      Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association ...
    • Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. 

      Dadaev, T; Saunders, EJ; Newcombe, PJ; Anokian, E; Leongamornlert, DA; Brook, MN; Cieza-Borrella, C; Mijuskovic, M; Wakerell, S; Olama, AAA; Schumacher, FR; Berndt, SI; Benlloch, S; Ahmed, M; Goh, C; Sheng, X; Zhang, Z; Muir, K; Govindasami, K; Lophatananon, A; Stevens, VL; Gapstur, SM; Carter, BD; Tangen, CM; Goodman, P; Thompson, IM; Batra, J; Chambers, S; Moya, L; Clements, J; Horvath, L; Tilley, W; Risbridger, G; Gronberg, H; Aly, M; Nordström, T; Pharoah, P; Pashayan, N; Schleutker, J; Tammela, TLJ; Sipeky, C; Auvinen, A; Albanes, D; Weinstein, S; Wolk, A; Hakansson, N; West, C; Dunning, AM; Burnet, N; Mucci, L; Giovannucci, E; Andriole, G; Cussenot, O; Cancel-Tassin, G; Koutros, S; Freeman, LEB; Sorensen, KD; Orntoft, TF; Borre, M; Maehle, L; Grindedal, EM; Neal, DE; Donovan, JL; Hamdy, FC; Martin, RM; Travis, RC; Key, TJ; Hamilton, RJ; Fleshner, NE; Finelli, A; Ingles, SA; Stern, MC; Rosenstein, B; Kerns, S; Ostrer, H; Lu, Y-J; Zhang, H-W; Feng, N; Mao, X; Guo, X; Wang, G; Sun, Z; Giles, GG; Southey, MC; MacInnis, RJ; FitzGerald, LM; Kibel, AS; Drake, BF; Vega, A; Gómez-Caamaño, A; Fachal, L; Szulkin, R; Eklund, M; Kogevinas, M; Llorca, J; Castaño-Vinyals, G; Penney, KL; Stampfer, M; Park, JY; Sellers, TA; Lin, H-Y; Stanford, JL; Cybulski, C; Wokolorczyk, D; Lubinski, J; Ostrander, EA; Geybels, MS; Nordestgaard, BG; Nielsen, SF; Weisher, M; Bisbjerg, R; Røder, MA; Iversen, P; Brenner, H; Cuk, K; Holleczek, B; Maier, C; Luedeke, M; Schnoeller, T; Kim, J; Logothetis, CJ; John, EM; Teixeira, MR; Paulo, P; Cardoso, M; Neuhausen, SL; Steele, L; Ding, YC; De Ruyck, K; De Meerleer, G; Ost, P; Razack, A; Lim, J; Teo, S-H; Lin, DW; Newcomb, LF; Lessel, D; Gamulin, M; Kulis, T; Kaneva, R; Usmani, N; Slavov, C; Mitev, V; Parliament, M; Singhal, S; Claessens, F; Joniau, S; Van den Broeck, T; Larkin, S; Townsend, PA; Aukim-Hastie, C; Gago-Dominguez, M; Castelao, JE; Martinez, ME; Roobol, MJ; Jenster, G; van Schaik, RHN; Menegaux, F; Truong, T; Koudou, YA; Xu, J; Khaw, K-T; Cannon-Albright, L; Pandha, H; Michael, A; Kierzek, A; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Lindstrom, S; Turman, C; Ma, J; Hunter, DJ; Riboli, E; Siddiq, A; Canzian, F; Kolonel, LN; Le Marchand, L; Hoover, RN; Machiela, MJ; Kraft, P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Freedman, M; Wiklund, F; Chanock, S; Henderson, BE; Easton, DF; Haiman, CA; Eeles, RA; Conti, DV; Kote-Jarai, Z (2018-06-11)
      Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable ...
    • Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. 

      Vigorito, E; Kuchenbaecker, KB; Beesley, J; Adlard, J; Agnarsson, BA; Andrulis, IL; Arun, BK; Barjhoux, L; Belotti, M; Benitez, J; Berger, A; Bojesen, A; Bonanni, B; Brewer, C; Caldes, T; Caligo, MA; Campbell, I; Chan, SB; Claes, KBM; Cohn, DE; Cook, J; Daly, MB; Damiola, F; Davidson, R; Pauw, AD; Delnatte, C; Diez, O; Domchek, SM; Dumont, M; Durda, K; Dworniczak, B; Easton, DF; Eccles, D; Edwinsdotter Ardnor, C; Eeles, R; Ejlertsen, B; Ellis, S; Evans, DG; Feliubadalo, L; Fostira, F; Foulkes, WD; Friedman, E; Frost, D; Gaddam, P; Ganz, PA; Garber, J; Garcia-Barberan, V; Gauthier-Villars, M; Gehrig, A; Gerdes, A-M; Giraud, S; Godwin, AK; Goldgar, DE; Hake, CR; Hansen, TVO; Healey, S; Hodgson, S; Hogervorst, FBL; Houdayer, C; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, A; Jacobs, L; Jakubowska, A; Janavicius, R; Jaworska-Bieniek, K; Jensen, UB; John, EM; Vijai, J; Karlan, BY; Kast, K; KConFab Investigators; Khan, S; Kwong, A; Laitman, Y; Lester, J; Lesueur, F; Liljegren, A; Lubinski, J; Mai, PL; Manoukian, S; Mazoyer, S; Meindl, A; Mensenkamp, AR; Montagna, M; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Olah, E; Olopade, OI; Ong, K-R; Osorio, A; Park, SK; Paulsson-Karlsson, Y; Pedersen, IS; Peissel, B; Peterlongo, P; Pfeiler, G; Phelan, CM; Piedmonte, M; Poppe, B; Pujana, MA; Radice, P; Rennert, G; Rodriguez, GC; Rookus, MA; Ross, EA; Schmutzler, RK; Simard, J; Singer, CF; Slavin, TP; Soucy, P; Southey, M; Steinemann, D; Stoppa-Lyonnet, D; Sukiennicki, G; Sutter, C; Szabo, CI; Tea, M-K; Teixeira, MR; Teo, S-H; Terry, MB; Thomassen, M; Tibiletti, MG; Tihomirova, L; Tognazzo, S; van Rensburg, EJ; Varesco, L; Varon-Mateeva, R; Vratimos, A; Weitzel, JN; McGuffog, L; Kirk, J; Toland, AE; Hamann, U; Lindor, N; Ramus, SJ; Greene, MH; Couch, FJ; Offit, K; Pharoah, PDP; Chenevix-Trench, G; Antoniou, AC (2016-01)
      Population-based genome wide association studies have identified a locus at 9p22.2 associated with ovarian cancer risk, which also modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We conducted fine-scale ...
    • First evaluation of the feasibility of MLC tracking using ultrasound motion estimation. 

      Fast, MF; O'Shea, TP; Nill, S; Oelfke, U; Harris, EJ (2016-08)
      Purpose To quantify the performance of the Clarity ultrasound (US) imaging system (Elekta AB, Stockholm, Sweden) for real-time dynamic multileaf collimator (MLC) tracking.Methods The Clarity calibration and quality assurance ...
    • First report on the reliability and validity of speech handicap index in native English-speaking patients with head and neck cancer. 

      Dwivedi, RC; St Rose, S; Roe, JWG; Chisholm, E; Elmiyeh, B; Nutting, CM; Clarke, PM; Kerawala, CJ; Rhys-Evans, PH; Harrington, KJ; Kazi, R (2011-03)
      Background Posttreatment speech problems are seen in nearly half of patients with head and neck cancer. Although there are many voice-specific scales, surprisingly there is no speech-specific questionnaire for English-speaking ...
    • Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. 

      Brunt, AM; Haviland, JS; Kirby, AM; Somaiah, N; Wheatley, DA; Bliss, JM; Yarnold, JR
      Introduction The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the ...
    • Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer 

      Merson, S; Yang, ZH; Brewer, D; Olmos, D; Eichholz, A; McCarthy, F; Fisher, G; Kovacs, G; Berney, DM; Foster, CS; Moller, H; Scardino, P; Cuzick, J; Cooper, CS; Clark, JP; Grp, TP (NATURE PUBLISHING GROUP, 2014-03-18)
      Background: Androgen receptor (AR)-gene amplification, found in 20-30% of castration-resistant prostate cancer (CRPCa) is proposed to develop as a consequence of hormone-deprivation therapy and be a prime cause of treatment ...
    • Focused ultrasound transducer spatial peak intensity estimation: a comparison of methods. 

      Civale, J; Rivens, I; Shaw, A; Ter Haar, G (2018-03-07)
      Characterisation of the spatial peak intensity at the focus of high intensity focused ultrasound transducers is difficult because of the risk of damage to hydrophone sensors at the high focal pressures generated. Hill et ...
    • Focused Ultrasound-Mediated Hyperthermia in Vitro: An Experimental Arrangement for Treating Cells under Tissue-Mimicking Conditions. 

      Brüningk, SC; Rivens, I; Mouratidis, P; Ter Haar, G (2019-12)
      An experimental arrangement that allows in vitro exposure of cells to focused ultrasound-mediated hyperthermia (43°C-55°C) in a tissue-mimicking phantom with biological, acoustic and thermal properties comparable to those ...
    • Four-dimensional imaging for radiotherapy planning in children and teenagers 

      Lavan, N (2021-02-28)
      Respiratory-related organ motion (RROM) is a potential source of geometric uncertainty in RT planning and delivery. Approaches to mitigate its effects are well described in adults. For example, four-dimensional computed ...